Siemens Healthineers Races to Refinance €13.9bn as €230m Buyback Kicks Off

Siemens Healthineers starts a €230M share repurchase while stock nears 52-week low and parent guarantee removal leaves a €13.9B refinancing challenge; diagnostics sale also explored.

Siemens Healthineers has launched a fresh €230 million share repurchase programme at a time when its stock is trading barely above a 52-week low and the company faces its most daunting financial challenge since listing: plugging a €13.9 billion funding hole once the parent guarantee disappears. The buyback, which began on 1 June, marks the smallest of three consecutive programmes and will run until at least 29 January next year. But the market’s focus is fixed on the bigger picture.

The stock has lost about a quarter of its value since the start of 2026 and changed hands at €33.64 in recent trading — just 1.7% above the 52-week trough. Behind the slide lies a dual anxiety: a downward revision to full?year forecasts and the unresolved question of how the group will refinance itself after Siemens AG ships its remaining 30% stake directly to its own shareholders. That move, now scheduled for a vote in February 2027, would strip away the parent guarantee that underpins roughly €13.9 billion of Siemens Healthineers’ debt.

Moody’s currently assigns the medtech group an A3 rating with a stable outlook, which keeps the capital?market door open. Even so, Barclays analysts estimate that standalone refinancing would add around €74 million to interest charges this year alone. So far the management team has not laid out a concrete plan. At an HSBC summit in Hong Kong days ago, answers remained vague.

The delay in the spin?off vote has disappointed many investors who had hoped for an extraordinary general meeting in the first half of this year. Instead, Siemens intends to reduce its holding from more than 67% to under 20% by early 2027, after which the stake would be classified as a pure financial investment.

Alongside the refinancing puzzle, Siemens Healthineers is exploring the sale of its diagnostics division, a business that continues to drag on group performance. Bloomberg reported that preliminary talks have taken place with private?equity firms including Blackstone, CVC and KKR, with a potential valuation north of €6 billion. No final decision has been taken.

The diagnostics weakness showed in the second fiscal quarter: comparable revenues in the unit fell 6.5% year on year, while imaging grew 6.1% and precision therapy added 4.7%. Group comparable revenue rose 3.1%, and adjusted earnings per share came in at €0.53, essentially flat on the prior?year period. For the full year, the company now expects comparable revenue expansion of 4.5% to 5.0%, down from an earlier forecast of 5% to 6%, and adjusted diluted earnings per share of between €2.20 and €2.30 — some ten cents below the previous target.

The new buyback programme operates under strict regulatory guardrails. Purchases are executed exclusively on Xetra with a mandated bank handling the timing. The price cannot exceed the day’s opening price by more than 10% nor fall more than 20% below it, and daily volume is capped at 25% of the average turnover over the preceding 20 trading days. A crucial detail: the repurchased shares are not slated for cancellation. They will primarily feed employee share?based compensation and other legally permissible purposes, thus offsetting dilution rather than shrinking the share count.

At 230 million euros, the programme is notably smaller than its predecessors — a €350 million buyback that ran from March 2025 to January 2026 and a €400 million programme from March 2023 to January 2024.

Technically, the stock’s relative strength index has climbed to 71, putting it in overbought territory despite a price that remains close to the floor. The management will have another chance to address investor concerns at the Goldman Sachs Global Healthcare Conference in Miami on 9 June, ahead of the next quarterly results due 31 July. Until a credible refinancing roadmap emerges, however, the structural uncertainty discount is likely to persist.